title: Thyroid peroxidase (TPO) as a tumor marker in the follow-up of differentiated thyroid carcinomas with surgical and ablative radioiodine therapy. An assessment after evaluation.
abstract: The clinical significance of serum thyroid peroxidase (TPO) for differentiated thyroid carcinomas(DTA) is estimated differently. In our preliminary studies it was found that TPO presented information extending those that from hTG. For further clarification a prospective follow-up study was performed including 66 female and 14 male total thyroidectomized patients with DTA for the time course of TPO and human thyroglobulin (hTg) in relation to the ablative radioidine therapy (ART). In 34/50 evaluable cases TPO levels showed an approximately analogous time course with hTg. In relation to the extension of residues, some cases presented increasing of TPO and hTG after radioiodine treatment. 6/7 patients suffering from extended postoperative residues with high anti hTg levels but without elevated TPO concentrations showed distinctly elevated TPO values. Therefore, TPO seems to be an indicator for the destruction of normal thyroid cells or thyroid tumor cells. The clinical value of TPO seems to be in the time being limited to DTA due to false negative hTg values. However, it should be possible that TPO can did the evaluation of thyroid specific therapy.
authors.affiliation: Universitätsklinikum der Technischen Universität Dresden/Klinik und Poliklinik für Nuklearmedizin, Germany.
authors.forename: W G
authors.initials: WG
authors.lastname: Franke
authors.forename: K
authors.initials: K
authors.lastname: Zöphel
authors.forename: G
authors.initials: G
authors.lastname: Wunderlich
authors.forename: A
authors.initials: A
authors.lastname: Kühne
authors.forename: C
authors.initials: C
authors.lastname: Schimming
authors.forename: J
authors.initials: J
authors.lastname: Kropp
authors.forename: J
authors.initials: J
authors.lastname: Bredow
mesh_terms: D001323:Autoantibodies / Q000097:blood; D014408:Biomarkers, Tumor / Q000097:blood*; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007118:Immunoassay; D007453:Iodide Peroxidase / Q000097:blood*; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D008163:Luminescent Measurements; D008297:Male; D015203:Reproducibility of Results; D013954:Thyroglobulin / Q000097:blood; D013964:Thyroid Neoplasms / Q000175:diagnosis / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery*; D013965:Thyroidectomy; D013972:Thyrotropin / Q000097:blood; D013974:Thyroxine / Q000097:blood; D014284:Triiodothyronine / Q000097:blood
chemical_list: D001323:Autoantibodies; D014408:Biomarkers, Tumor; D007457:Iodine Radioisotopes; D014284:Triiodothyronine; D013972:Thyrotropin; D013954:Thyroglobulin; D007453:Iodide Peroxidase; D013974:Thyroxine